Neurogene Inc. Reports Executive Changes and Compensation Adjustments
Ticker: NGNE · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1404644
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Neurogene Inc. just announced executive and compensation changes, keep an eye on leadership shifts!**
AI Summary
Neurogene Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to the departure or election of directors or certain officers and compensatory arrangements for certain officers. This indicates potential changes in the company's leadership or executive compensation structure.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial health adjustments within a company, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future company direction and stability, warranting careful monitoring.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 21, 2024 (date) — Filed as of date
- Delaware (company) — State of Incorporation
- New York, NY (company) — Business address location
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
What is the primary subject matter of this 8-K filing?
The primary subject matter of this 8-K filing is the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on February 21, 2024.
What is the full legal name of the registrant company?
The full legal name of the registrant company is Neurogene Inc.
What is the business address of Neurogene Inc. as stated in the filing?
The business address of Neurogene Inc. is 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-02-21 16:07:08
Key Financial Figures
- $0.000001 — ich registered Common Stock, par value $0.000001 per share NGNE The Nasdaq Global Ma
- $370,000 — Ms. Cochener a base salary for 2024 of $370,000 on an annualized basis, and she will be
Filing Documents
- d699526d8k.htm (8-K) — 22KB
- 0001193125-24-041440.txt ( ) — 141KB
- ngne-20240215.xsd (EX-101.SCH) — 3KB
- ngne-20240215_lab.xml (EX-101.LAB) — 18KB
- ngne-20240215_pre.xml (EX-101.PRE) — 11KB
- d699526d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROGENE INC. Date: February 21, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President and Chief Financial Officer